Trials / Completed
CompletedNCT04464408
Favipiravir Therapy in Adults With Mild COVID-19
A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 231 (actual)
- Sponsor
- King Abdullah International Medical Research Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Favipiravir is a selective and potent inhibitor of influenza viral RNA polymerase. It acts as a purine analogue, which selectively inhibits viral RNA-dependent RNA polymerase (RdRps). It has the characteristic of acting on RNA viruses including Ebola and Coronaviruses especially novel coronavirus (2019-nCoV). The purpose of this study is to evaluate the clinical efficacy and safety of Favipiravir in comparison to placebo in the treatment of mild COVID-19 cases. It is a Multicenter, randomized double-blinded, parallel-group trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Favipiravir | 1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily |
| DRUG | Placebo | (9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days) |
Timeline
- Start date
- 2020-07-23
- Primary completion
- 2021-08-04
- Completion
- 2021-08-04
- First posted
- 2020-07-09
- Last updated
- 2021-11-05
Locations
7 sites across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT04464408. Inclusion in this directory is not an endorsement.